Company Encyclopedia
View More
name
Vor BioPharma
VOR.US
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant.
1.875 T
VOR.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. Stock Market Midday Update: Analyst Optimism Fails to Halt Stock Price Decline, Vor BioPharma's Restructuring Financing Fails to Boost Market Confidence

    Vor BioPharma fell 12.21%; Precision BioSciences rose 17.52%, with a trading volume of USD 5.153 billion; Regeneron Pharmaceuticals rose 5.60%, with a trading volume of USD 1.086 billion; Gilead Sciences fell 2.19%, with a trading volume of USD 512 million; AbbVie fell 1.34%, with a market capitalization of USD 405.9 billion

    Tracking Unusual Activity·
    US
    VOR
    -12.28%
    Tracking Unusual Activity·
    US
    VOR
    -12.28%

    H.C. Wainwright Sticks to Its Buy Rating for Vor Biopharma (VOR)

    H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating for Vor Biopharma with a price target of $32.00. Ramakanth, a 5-star analyst with a 17.9% average return, focuses on healthcare stocks. The consensus on Vor Biopharma is a Strong Buy with an average price target of $50.33.

    Tip Ranks·
    US
    VOR
    -12.28%
    Tip Ranks·
    US
    VOR
    -12.28%

    Vor Biopharma Reports Q3 2025 Financial Results and Strategic Updates

    Vor Biopharma reported a Q3 2025 net loss of $812.7 million due to warrant liabilities and R&D expenses. Despite this, it raised capital, increasing cash reserves to $160.5 million. The company restructured operations, terminating a lease to focus on clinical programs. Vor Biopharma aims to advance trials and seek further funding for growth.

    Tip Ranks·
    US
    VOR
    -12.28%
    Tip Ranks·
    US
    VOR
    -12.28%

    Vor BioPharma | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    VOR
    -12.28%
    LB filings·
    US
    VOR
    -12.28%

    Vor Biopharma reports third quarter loss and reduced R&D expenses

    Vor Biopharma Inc. reported a net loss of $812.7 million for Q3 2025, a significant increase from $27.6 million in Q3 2024. Operating expenses slightly decreased to $28.1 million, with R&D expenses down to $14.1 million due to reduced stock-based compensation and headcount. Cash reserves were $170.5 million, with funding projected into Q2 2027. The company expanded its leadership and highlighted late-stage data for telitacicept.

    Reuters·
    US
    VOR
    -12.28%
    Reuters·
    US
    VOR
    -12.28%